Comparative analysis of the methods of drug and protein delivery for the treatment of cancer, genetic diseases and diagnostics

Todorova, Roumiana

doi:10.3109/10717544.2011.600783

Cited by 17 publications

(16 citation statements)

References 95 publications

(115 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The radiolabelled vitamin derivatives, used to label the tumour tissue, accumulate radioactivity in normal tissue, thus affecting cells (Todorova 2011). The survivors of malignant bone tumours, where the radiation therapy is associated with a linear dose -response relationship, are at a 14 R. Todorova and A.T Atanasov particularly increased risk of developing distant metastases.…”

Section: Radioprotective Effectmentioning

confidence: 99%

“…The risk of secondary neoplasms after high-dose chemotherapy in 1 -2% of patients imposes the development of new treatment strategies for highly aggressive tumours (Todorova 2014). An effective drug must be active only in the diseased cell, and the chemotherapy agents must be able to kill tumour cells selectively, leaving the normal cells unharmed (Todorova 2011). Plants not interfering with the antitumour efficiency of cyclophosphamide can significantly reduce the toxic side effects of chemotherapy in patients.…”

Section: Chemoprotective Effectmentioning

confidence: 99%

“…Further studies may include test of total extracts, purified complexes and compounds for antioxidant activity and cytotoxicity to allow large-scale production of bioactive compounds with useful application; isolation of bioactive compounds or bioactive complexes for their application in pharmacology, veterinary medicine and cosmetics; developing of in vitro collection of species (Djilianov et al 2009). The new developing technologies of drug delivery and targeting offer a chance to improve the therapeutic possibilities of the existing drugs as well as to develop novel therapeutics (Todorova 2011). Syringic acid acts on diabetic cataract (DC) pathogenesis (Wei et al 2012).…”

Section: Pharmacological Importancementioning

confidence: 99%

See 2 more Smart Citations

Haberlea rhodopensis: pharmaceutical and medical potential as a food additive

Todorova

Atanasov

2015

Natural Product Research

Self Cite

View full text Add to dashboard Cite

This review discusses the potential of Haberlea rhodopensis as a food additive. The following are described: plant distribution, reproduction, cultivation, propagation and resurrection properties; extraction, isolation and screening of biologically active compounds; metabolite changes during dehydration; phytotherapy-related properties such as antioxidant potential and free radical-scavenging activities, antioxidant skin effect, antibacterial activity, cytotoxic activity and cancer-modulating effect, radioprotective effect, chemoprotective effect, immunologic effect; present use in homoeopathy and cosmetics, pharmacological and economical importance; perspectives based on the ethnobotanical data for medicinal, cosmetic or ritual attributes. H. rhodopensis showed unique medical and pharmaceutical potential, related to antioxidant, antimicrobial, antimutagenic, anticancer, radioprotective, chemoprotective and immunological properties. H. rhodopensis extracts lack any cytotoxic activity and could be used in phytotherapy. The metabolic profiling of H. rhodopensis extracts revealed the presence of biologically active compounds, possessing antiradical and other physiological activities, useful for design of in vitro synthesised analogues and drugs.

show abstract

Section: Radioprotective Effectmentioning

confidence: 99%

Section: Chemoprotective Effectmentioning

confidence: 99%

Section: Pharmacological Importancementioning

confidence: 99%

See 1 more Smart Citation

Haberlea rhodopensis: pharmaceutical and medical potential as a food additive

Todorova

Atanasov

2015

Natural Product Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…But it has potentially risk that viral vectors may infect healthy cell adjacent to the target cell (Moss, 2014 ), even can lead to patient death because of inflammatory immune responses induced by adenoviral vectors (Chuah et al., 2003 ), and the size of genetic materials inserted into cell is limited (El-Aneed, 2004 ; Lv et al., 2006 ). Chemical methods commonly include calcium phosphate coprecipitation, high molecular weight cationic polymers, cationic lipid and cationic amino acid (Holmen et al., 1995 ; Washbourne & McAllister, 2002 ; Kim & Eberwine, 2010 ; Todorova, 2011 ). Compared with biological method, the chemical method has advantages of no size limitation and less cytotoxicity.…”

Section: Introductionmentioning

confidence: 99%

Advanced physical techniques for gene delivery based on membrane perforation

et al. 2018

View full text Add to dashboard Cite

Gene delivery as a promising and valid tool has been used for treating many serious diseases that conventional drug therapies cannot cure. Due to the advancement of physical technology and nanotechnology, advanced physical gene delivery methods such as electroporation, magnetoporation, sonoporation and optoporation have been extensively developed and are receiving increasing attention, which have the advantages of briefness and nontoxicity. This review introduces the technique detail of membrane perforation, with a brief discussion for future development, with special emphasis on nanoparticles mediated optoporation that have developed as an new alternative transfection technique in the last two decades. In particular, the advanced physical approaches development and new technology are highlighted, which intends to stimulate rapid advancement of perforation techniques, develop new delivery strategies and accelerate application of these techniques in clinic.

show abstract

“…Although cell-penetrating peptides (CPPs) providing an effective approach to deliver cargoes into cells (Todorova, 2011;Li & Tsui, 2014) benefit from their transport ability because of their good properties of biodegradability, biocompatibility, low toxicity, and ease of synthesis (Heitz et al, 2009), the application of CPPs is limited due to their several drawbacks, including lack of cell specificity and low efficiency of BBB penetration. To address these problems, our group have recently developed a novel CPPs (named RDP), derived from rabies virus glycoprotein, to targetingdeliver proteins into brain cells following the systemic administration (Fu et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

A novel cell-permeable RDP-p53 fusion protein for specific inhibition on the growth of cancerous neural cells

Zhang

2015

Drug Delivery

View full text Add to dashboard Cite

Objective: There is 25-35% mutation rate of p53 in cancerous neural cells and this rate reaches 70-76% in glioma cell line. Complement of wild-type p53 has become a potential strategy for protein therapy of cancerous neural cells. Here we investigated the feasibility of a novel RDP-p53 fusion protein for anti-proliferation of cancerous neural cell and the possible mechanism, which would provide an effective approach for targeted delivery of p53 protein to treat cancerous neural cells. Methods: The RDP-p53 fusion proteins are expressed in Escherichia coli, and they are labeled with FITC and rhodamine B by chemical modification. The fluorescence-labeled proteins are added to human hepatocellular carcinoma cells (HepG-2) and human neuroblastoma cells (SH-SY5Y) in order to investigate the possibility of RDP enhancing the cell uptake efficiency into neural cells as a cell-permeable carrier. The inhibitory effect of RDP-p53 on SH-SY5Y and human glioma cells (U251) was evaluated by MTT assay. Moreover, the anti-proliferation mechanism of RDP-p53 was determined by Apoptosis and Necrosis Assay Kit and flow cytometric analysis. Results:The results showed that RDP-p53 could enter SH-SY5Y cells with high efficiency and selectively inhibit the growth of cancerous neural cells, including SH-SY5Y and U251. Also, cell apoptosis pathway and cell-cycle arrest at the G2/M phase were associated with the inhibition mechanism of RDP-p53 according to the data of flow cytometric analysis. Conclusions: RDP-p53 could be a novel antitumor candidate for targeting treatment of cancerous neural cells.

show abstract

Comparative analysis of the methods of drug and protein delivery for the treatment of cancer, genetic diseases and diagnostics

Cited by 17 publications

References 95 publications

Haberlea rhodopensis: pharmaceutical and medical potential as a food additive

Haberlea rhodopensis: pharmaceutical and medical potential as a food additive

Advanced physical techniques for gene delivery based on membrane perforation

A novel cell-permeable RDP-p53 fusion protein for specific inhibition on the growth of cancerous neural cells

Contact Info

Product

Resources

About